اولاد کے سامنے بےحیائی کا نتیجہ ویڈیو پر کلک کریں

Alzheimer dementia mortality is expanding in the United States, while coronary illness and growth demise rates have diminished no less than 25% recently.1 New heart and disease medications oftentimes stand out as truly newsworthy. Be that as it may, the appraisal of Alzheimer's treatment is stark: "… there are right now no medicines that change the course of this dynamic cerebrum issue," [original italics] so expressed in the 2014-2015 Alzheimer Disease Progress Report by the National Institute of Aging (NIA).2 President Obama marked the National Alzheimer's Project Act in 2011, with an objective of having successful treatment by 2025. Presently five years after the fact, clinicaltrials.gov records less than 120 Alzheimer drug trials in the US selecting subjects, with almost 500,000 new patients every year. Coronary illness has just about 800 medication trials, while grown-up growth has very nearly 4000 medication trials recorded. Clinical exploration endeavors in an ailment are reflected by the quantity of related clinical trial distributions. We inspected Pub Med information alongside US mortality insights to demonstrate the juxtaposition of those measures for Alzheimer's ailment, coronary illness, disease and six other driving reasons for death, (Figure 1).3,4 Diminishments in US malady mortality have been corresponding to the quantity of trials led in every ailment with the exception of Alzheimer's, amid the years 2000-2013. Alzheimer's malady is a noteworthy exception, since mortality is expanding while the quantity of companion checked on distributions falls behind different conditions.